Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
164 participants
INTERVENTIONAL
2023-09-19
2027-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan
NCT01843426
A Study to Obtain Imaging Data in 40 Patients Having Transcatheter Aortic Valve Implantation (TAVI)
NCT06596460
MRI in Transcatheter Aortic Valve Replacement Patients
NCT05603026
Multi Modal Cardiac Imaging Prior Transcatheter Aortic Valve Implantation
NCT01805739
Cardiac Vascular Reconstruction DynaCT for TAVI Procedures
NCT02031796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
A cohort will be given a 1/3rd reduced dose of iodinated contrast agent (33 ml).
Iodinated Contrast Agent (Omnipaque)
Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.
Dual Energy CT
Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.
Cohort 2
If imaging with 1/3 dose is satisfactory, a second cohort with 1/4th the standard dosage (25 ml) will be assessed. If images are not satisfactory, contrast dose will be increased to 50 ml.
Iodinated Contrast Agent (Omnipaque)
Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.
Dual Energy CT
Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iodinated Contrast Agent (Omnipaque)
Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.
Dual Energy CT
Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Allergy to intravenous contrast not controlled by steroids or benadryl
* GFR\<30
18 Years
88 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Maryland, Baltimore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vikas Kundra
Chief of Oncologic Imaging, Dept. of Radiology and Nuclear Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Maryland Medical Center
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Lai MZ, Duzgunes N, Szoka FC. Effects of replacement of the hydroxyl group of cholesterol and tocopherol on the thermotropic behavior of phospholipid membranes. Biochemistry. 1985 Mar 26;24(7):1646-53. doi: 10.1021/bi00328a012.
Gurm HS, Dixon SR, Smith DE, Share D, Lalonde T, Greenbaum A, Moscucci M; BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) Registry. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2011 Aug 23;58(9):907-14. doi: 10.1016/j.jacc.2011.05.023.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HP-00104800
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.